Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

More News! 10 Jun 2017

This Turkish Bioartist Creates Beautiful Maps out of Fungi

Selin Balci uses fungi as a medium to create living maps that explore the complexity of microscopic life and its similarity with human behavior. Selin Balci got a degree in microbiology from Istanbul University and worked in research for 5 years before turning to art. Her work combines her experience culturing fungi and mold with creative experimentation to obtain colorful […]

June 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Jun 2017

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year’s edition of the American Society of Clinical Oncology (ASCO) meeting, with impressive results from some of the most novel approaches under development to fight multiple forms of cancer. From a […]

June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

Imperial College London incubator Hammersmith Hospital White City

News and Trends 6 Jun 2017

Imperial College Moves its Startup Incubator to a Bigger Facility in West London

Last Friday, the Duke of York opened Imperial’s newest facilities in the White City campus, where the university is relocating its startup incubator. Imperial College’s startup incubator, previously located at Imperial’s South Kensington campus, just got a significant upgrade with brand new facilities that opened last week in Imperial College’s White City campus. The new space, aptly renamed the White City […]

June 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Scenic Biotech Genetic Off Switch Cancer Rare Disease

News and Trends 5 Jun 2017

New Dutch Biotech Gets Funding to Find Genetic Off Switches

Scenic Biotech is applying a technology to identify first-in-class therapeutic targets that has secured it €6.5M in Series A. Scenic Biotech, founded in Amsterdam just this year, has raised €6.5M to exploit the potential of a technology to discover new types of disease-related genes with applications in cancer and rare genetic diseases. The company, created in […]

June 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jun 2017

The Microscopic World of Bacteria Comes to Life with Sculpture

Aimee Lax is a British sculptor that explores the bizarre world of microscopic life by making beautiful sculptures that magnify their tiny size. “There’s a whole world out there that we never see, but it’s all here, it’s all real,” says Aimee Lax. Her piece Bacteriophages was included in the permanent exhibition Invisible You – The […]

June 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Inthera Bioscience Protein Interactions Cancer

News and Trends 31 May 2017

Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer

Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor. Members of Novo Seeds and […]

May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 31 May 2017

Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III

Strekin has closed a Series C financing round that will fund the progression of its lead candidate for hearing loss to Phase III. Based in Basel, Strekin focuses on repurposing existing drugs by discovering new mechanisms of action. The company has now received €9.2M (CHF 10M) in Series C to fund the company’s activity until 2019 […]

May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández

trust me im an artist amsterdam bioart exhibition

News and Trends 27 May 2017

“Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam

The exhibition in Amsterdam showcases the works of ten bioartists questioning the huge complexity of ethics in the rapidly developing field of biotechnology. The Waag Society has brought together bioartists from all over Europe that explore topics like gene editing, antibiotics, human tissue culture, public health and personalized medicine. After a series of performances discussed […]

May 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 24 May 2017

Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors

Oxford BioDynamics will start the development of an epigenetic test to screen patients for a favorable response to anti-PD-L1 drugs. Oxford BioDynamics has announced an agreement with two of the top 10 global pharma to initiate the development of a blood-based test to predict the response to PD-L1 checkpoint inhibitors in patients with non-small cell […]

May 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Tolerogenixx cell therapy transplant High Tech Grunderfonds

More News! 24 May 2017

Seed Funding for a German Cell Therapy to Prevent Transplant Rejection

TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Gründerfonds. TolerogenixX is a startup from the Heidelberg University Hospital that develops personalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an “impressive efficacy” in preventing the rejection of […]

May 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 24 May 2017

What Happens when the Immune System Attacks Life-Saving Drugs?

Immunogenicity has been largely disregarded despite its huge impact on the performance of biological drugs. What is it and how can we fight it? Immunogenicity can be a huge problem. Affecting especially protein-based drugs, this process consists in the development of anti-drug antibodies (ADAs) against a molecule that, in most cases, is saving the life […]

May 24, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 May 2017

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […]

May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us